Literature DB >> 25607474

BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.

Jean-Marie Tan1, Lynlee L Lin1, Duncan Lambie2, Ross Flewell-Smith1, Kasturee Jagirdar1, Helmut Schaider1, Richard A Sturm1, Tarl W Prow1, H Peter Soyer1.   

Abstract

IMPORTANCE: The BRAF V600E mutation accounts for the majority of BRAF mutations found in cutaneous melanoma and is also commonly found in nevi. We used dermoscopy-targeted sampling and a microbiopsy device coupled with DNA sequence analysis to highlight BRAF V600E heterogeneity within a multicomponent melanocytic proliferation. This sampling technique demonstrates the prospect of in vivo application in a clinical setting. OBSERVATIONS: A man in his 50s with Fitzpatrick skin type II presented with an irregularly pigmented melanocytic lesion on his back that met melanoma-specific dermoscopic criteria, and diagnostic shave excision of the lesion was performed. Histopathologic analysis revealed a melanoma in situ arising in a dysplastic nevus. Dermoscopy-targeted microbiopsy specimens were taken across the lesion, and genotyping was carried out on extracted DNA samples for BRAF and NRAS mutations. The melanoma in situ showed only BRAF wild-type results, while the dysplastic nevus showed both BRAF wild-type and BRAF V600E mutations. Sequencing in all DNA samples revealed NRAS wild-type genotype. CONCLUSIONS AND RELEVANCE: Dermoscopy-targeted sampling and genotyping of a melanoma in situ arising in a dysplastic nevus revealed a phenotype-genotype paradox that confounds the exclusive significance of BRAF and NRAS mutations in melanoma pathogenesis. Further studies are required to investigate the importance of other candidate genes linked to melanomagenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25607474     DOI: 10.1001/jamadermatol.2014.3775

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  6 in total

1.  Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases.

Authors:  Ying Ding; Cong Wang; Xuejie Li; Yangyang Jiang; Ping Mei; Wenbin Huang; Guoxin Song; Jinsong Wang; Guoqiang Ping; Ran Hu; Chen Miao; Xiao He; Gang Chen; Hai Li; Yan Zhu; Zhihong Zhang
Journal:  Diagn Pathol       Date:  2018-08-16       Impact factor: 2.644

Review 2.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

3.  Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.

Authors:  Jeffrey Zhao; Carlos Galvez; Kathryn Eby Beckermann; Douglas B Johnson; Jeffrey A Sosman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-08-11

Review 4.  Genetics of melanocytic nevi.

Authors:  Mi Ryung Roh; Philip Eliades; Sameer Gupta; Hensin Tsao
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

Review 5.  A review of microsampling techniques and their social impact.

Authors:  Benson U W Lei; Tarl W Prow
Journal:  Biomed Microdevices       Date:  2019-08-15       Impact factor: 2.838

6.  Prevalence and Main Determinants of BRAF V600E Mutation in Dysplastic and Congenital Nevi.

Authors:  Alierza Ghanadan; Tahereh Yousefi; Kambiz Kamyab-Hesari; Vahidehsadat Azhari; Maryam Nasimi
Journal:  Iran J Pathol       Date:  2020-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.